Decreasing the Incidence of Delirium After Cardiac Surgery

Sponsor
University of California, Los Angeles (Other)
Overall Status
Withdrawn
CT.gov ID
NCT02119806
Collaborator
(none)
0
1
2

Study Details

Study Description

Brief Summary

In critically ill surgical patients, delirium (confusion and disorientation) is extremely common and is associated with longer hospital length of stay, mortality, cost, and long term cognitive impairment. The goal of the study is to establish whether benzodiazepines (a sedative, anti-anxiety drug) should be used as part of standard of care or be eliminated by comparing the chances of delirium in cardiac surgery patients between two groups: a group that receives benzodiazepines during surgery versus a group that does not receive benzodiazepines during surgery. Benzodiazepines have historically been used in cardiac anesthesia to decrease the risk of anesthesia awareness. The current standard of care is to keep the patient on inhaled anesthesia throughout the surgery which eliminates the need for intraoperative use of benzodiazepines. Benzodiazepines are still used based on practitioner preference. Findings of this study will allow all anesthesiologists to make more informed decisions about what level of care our patients need.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

In critically ill surgical patients, delirium is extremely common and is associated with longer hospital length of stay, mortality, cost, and long term cognitive impairment. Benzodiazepine usage is common in anesthetic practice, and ICU literature demonstrates that limiting post-operative benzodiazepines decreases the incidence of delirium. However, the avoidance of preoperative and intraoperative benzodiazepines during cardiac surgery has not been studied in terms of its effect on delirium. The goal of the study is establish whether benzodiazepines should be used as part of standard of care or be eliminated by comparing the incidence of delirium in cardiac surgical patients when randomized to a group that receives benzodiazepines versus a group that does not receive benzodiazepines.

Potential subjects will be identified and recruited the day before surgery by primary investigators. Patients undergoing coronary artery bypass grafting or single valve procedures that consent to participate will be enrolled in the study. These patients may be consented during the pre-operative period. Patients will be informed that whether they enroll in the study or not, they will be receiving standard clinical care. Only subjects meeting all inclusion criteria and requirements for continuation in the study will be consented.

Patient will be randomized by age (age is a predictor of delirium) to 3 groups:
  • 80 years of age;

  • 70-80 years of age;

  • < 70 years of age.

Within these 3 groups, patients will be randomized to receive benzodiazepines during cardiac surgery or not. The anesthesiologist in the operating room will not be blinded to the group; however, the intensive care physician evaluating for delirium will be blinded to the treatment groups.

Benzodiazepine group:
  1. Premedication 0.02mg/kg-0.1mg/kg of midazolam;

  2. Maintenance 0.8 minimum alveolar concentration of inhaled anesthetic (MAC) and 10-30mcg/kg of fentanyl;

  3. Postoperative 10-100mcg/kg/min of propofol

Non-benzodiazepine group:
  1. Premedication 0-50mg of propofol and/or 0-250mcg of fentanyl;

  2. Maintenance 0.8 minimum alveolar concentration of inhaled anesthetic (MAC) and 10-30mcg/kg of fentanyl;

  3. Postoperative 10-100mcg/kg/min of propofol

Delirium can now be reliably diagnosed by non-psychiatrists in critically ill patients in less than 2 minutes through the use of validated monitoring instruments such as the Confusion Assessment Method for the ICU (CAM-ICU).

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Decreasing the Incidence of Delirium After Cardiac Surgery
Anticipated Study Start Date :
Aug 1, 2017
Anticipated Primary Completion Date :
Aug 1, 2017
Anticipated Study Completion Date :
Aug 1, 2017

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Benzodiazepine group

Premedication 0.02mg/kg-0.1mg/kg of Benzodiazepine ; Maintenance 0.8 minimum alveolar concentration of inhaled anesthetic (MAC) and 10-30mcg/kg of fentanyl; Postoperative 10-100mcg/kg/min of propofol

Drug: Benzodiazepine
Receive as premedication in the Benzodiazepine group.
Other Names:
  • Midazolam
  • Versed
  • Drug: Fentanyl
    Receive as maintenance in the Benzodiazepine group. Can receive as premedication in the Non-Benzodiazepine group. Receive as maintenance in the Non-Benzodiazepine group.
    Other Names:
  • Fentanil
  • Drug: Propofol
    Receive postoperatively in the Benzodiazepine group. Can receive as premedication in the Non-Benzodiazepine group. Receive postoperatively in the Non-Can receive as premedication in the Non-Benzodiazepine group.
    Other Names:
  • Diprivan
  • Active Comparator: Non-benzodiazepine group

    Premedication 0-50mg of propofol and/or 0-250mcg of fentanyl; Maintenance 0.8 minimum alveolar concentration of inhaled anesthetic (MAC) and 10-30mcg/kg of fentanyl; Postoperative 10-100mcg/kg/min of propofol

    Drug: Fentanyl
    Receive as maintenance in the Benzodiazepine group. Can receive as premedication in the Non-Benzodiazepine group. Receive as maintenance in the Non-Benzodiazepine group.
    Other Names:
  • Fentanil
  • Drug: Propofol
    Receive postoperatively in the Benzodiazepine group. Can receive as premedication in the Non-Benzodiazepine group. Receive postoperatively in the Non-Can receive as premedication in the Non-Benzodiazepine group.
    Other Names:
  • Diprivan
  • Outcome Measures

    Primary Outcome Measures

    1. Delirium [less than 2 minutes]

      Delirium can now be reliably diagnosed by non-psychiatrists in critically ill patients in less than 2 minutes through the use of validated monitoring instruments such as the Confusion Assessment Method for the ICU (CAM-ICU)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Adult patients' undergoing coronary artery bypass grafting or single valve procedures.
    Exclusion Criteria:
    • Patients who have baseline cognitive dysfunction,

    • Patients with hearing problems,

    • Patients currently on benzodiazepines

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Ronald Reagan UCLA Medical Center, Department of Anesthesiology Los Angeles California United States 90095

    Sponsors and Collaborators

    • University of California, Los Angeles

    Investigators

    • Principal Investigator: Jacques Neelankavil, M.D., University of California, Los Angeles

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Jacques Neelankavil, HS Assistant Clinical Professor, University of California, Los Angeles
    ClinicalTrials.gov Identifier:
    NCT02119806
    Other Study ID Numbers:
    • Delirium 13-001412
    First Posted:
    Apr 22, 2014
    Last Update Posted:
    Jun 12, 2018
    Last Verified:
    Jun 1, 2018
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Jacques Neelankavil, HS Assistant Clinical Professor, University of California, Los Angeles
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 12, 2018